欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (5): 548-551.

• 药物治疗学 • 上一篇    下一篇

布地奈德混悬液雾化维持治疗重度持续性哮喘疗效与安全性观察

满振珍1, 孙书芳2, 郝万明1, 韩伟1, 唐华平1   

  1. 1青岛大学医学院附属青岛市市立医院东院呼吸科,青岛266071,山东;
    2青岛市中心血站血源管理科,青岛266071,山东
  • 收稿日期:2013-10-16 修回日期:2014-04-28 出版日期:2014-05-26 发布日期:2014-06-05
  • 通讯作者: 唐华平,男,主任医师,研究方向:慢性气道炎症性疾病。Tel: 0532-88905522 E-mail: sallyhan1@163.com
  • 作者简介:满振珍,女,研究生在读,研究方向:慢性气道炎症性疾病。Tel: 15192719859 E-mail: manzhen2006@126.com

Nebulized Budesonide suspension in maintenance therapy of patients with severe persistent asthma

MAN Zhen-zhen1, SUN Shu-fang2, HAO Wan-ming1, HAN Wei1, TANG Hua-ping1   

  1. 1Department of Respiratory Medicine,Qingdao Municipal Hospital(East Hospital),Medicine College of Qingdao University,Qingdao 266071,Shandong,China;
    2Department of Blood Management,Qingdao Blood Bank,Qingdao 266071,Shandong,China
  • Received:2013-10-16 Revised:2014-04-28 Online:2014-05-26 Published:2014-06-05

摘要: 目的:评价布地奈德混悬液雾化吸入治疗重度持续性哮喘病人8周的疗效和安全性。方法:重度持续性哮喘病人24例,筛选后给予雾化吸入布地奈德混悬液8周,收集治疗4周、8周后肺功能(FEV1)、症状评分、沙丁胺醇气雾剂(万托林)使用情况,分别与治疗前进行比较,观察尿皮质醇水平的变化及副作用情况。结果:21例病人筛选成功,20例完成治疗,治疗后4周、8周的FEV1、症状评分、万托林使用情况较前改善(P<0.05)。治疗后第4、8周FEV1分别改善 12.7%、13.7%,日间症状评分分别改善 31.3%、29.8%,夜间症状评分分别改善 32.8%、36.8%,每日使用万托林的次数分别减少 39.1%、41.2%,治疗后病人的尿皮质醇在正常范围内,整个治疗过程中无严重副作用发生。结论:布地奈德混悬液维持治疗重度持续性哮喘病人有效,且安全性好。

关键词: 布地奈德, 重度哮喘, 治疗, 肺功能, 评分

Abstract: AIM: To observe the curative effect and safety of Budesonide inhalation suspension (BIS) in maintenance therapy of patients with severe persistent asthma .METHODS: 24 patients with severe asthma were screened,the patients enrolled were treated with BIS 2 mg twice a day and salbutamol aerosol as need for 8 weeks. The curative effect outcomes after 4 treating weeks and 8 treating weeks, including pulmonary function test (FEV1), asthma symptom scores,salbutamol aerosol use, as well as the side effects index at the end of study, such as urocortisol level, were collected and compared before study(baseline).RESULTS: 21 patients were successfully enrolled,20 of which completed the treatment. The curative effect outcomes were improved compared with the baseline(P<0.05), FEV1 was improved by 12.7% and 13.7%, daytime symptom scores were improved by 31.3% and 29.8%, night symptom scores were improved by 32.8% and 36.8%, times of Ventolin daily use were reduced by 39.1% and 41.2% after 4 weeks treatment and 8 weeks treatment respectively. After 8 weeks treatment, urocortisol in all patients was normal range and no severe side effect occurred.CONCLUSION: BIS has good curative effect and safety in treating patients with severe persistent asthma as maintenance therapy.

Key words: Budesonide inhalation suspension, severe persistent asthma, therapy, pulmonary function test, score

中图分类号: